E.U. to consider repackaging controls

Drug distributors who arbitrage the price differences across the European Union could see their $5.5 billion a year trade severely curtailed under proposed legislation set to be unveiled by the European Commission later this month. Report

Suggested Articles

With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.

Investors are clamoring for a CVR created in the BMS-Celgene deal, but it will only pay off if the FDA approves three hot pipeline projects.

Muzammil Mansuri, Sanofi’s EVP of strategy and business development since February 2016, is retiring at the end of November.